Zanamivir for the treatment of clinically diagnosed influenza in clinical practice: Results of the valuable-insights-from-patients study

Clinical Drug Investigation

Volumn 20, Issue 5, 2000, Pages 327-336

  Johnson, R ^a   Schweinle, J E ^b   Burroughs, S ^b  

^a IQVIA   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ZANAMIVIR;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL PRACTICE; DEVICE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TOLERABILITY; FEVER; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MYALGIA; PRIORITY JOURNAL; QUESTIONNAIRE; SYMPTOMATOLOGY; UNITED STATES;

EID: 0033710658     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200020050-00004     Document Type: Article

References (15)

1. Underused options for preventing and treating influenza
2. Deaths: Final data for 1997
3. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine
4. Prevention and control of influenza recommendations of the Advisory Committee on Immunization Practices (ACIP)
5. Chemotherapeutic control of influenza
6. Neuraminidase inhibitors for treatment of influenza A and B infections
7. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections
8. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections
9. The efficacy and safety of inhaled zanamivir in the treatment of influenza in otherwise healthy and 'high risk' individuals in North America
10. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: A randomized, double-blind, placebo-controlled European study
11. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: Pooled efficacy analysis
12. Management of Influenza in the Southern Hemisphere Trialists. Treating influenza with zanamivir
13. Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during Phase II clinical efficacy studies
14. Zanamivir, a new targeted therapy in the treatment of influenza: A patient perspective assessed by questionnaire
15. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: A randomized controlled trial